Loading…
Biologics arm of 3SBio making monoclonal antibodies and biosimilars for autoimmune disease and oncology.
Biologics arm of 3SBio making monoclonal antibodies and biosimilars for autoimmune disease and oncology.
In one line: A China biosimilar unit akin to a small Amgen biosimilars arm.
Moat: narrow (process know-how, IP / patents). In-house antibody manufacturing and an affiliate relationship with parent 3SBio's commercial network.
Headquarters: Shenyang, China · Founded: 2002 · Employees: 1,012
Size Sunshine Guojian Pharmaceutical (Shanghai) (688336.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $4.47B, the 573rd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥33.27 on 6 Nov 2026.
Performance Over six months the shares fell 34.1%, against +3.7% for the median peer and -16.4% for the China market (cap-weighted) — 2nd lowest of 20 in its peer set.
Growth Revenue grew 227.2% over the last twelve months (peer median +9.1%); the operating margin is 73.8% (peer median 17.6%).
Valuation It trades at 46.9× forward earnings against a peer median of 26.9× (3rd most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +45%, so the hurdle is -42 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 23.7 points above its cost of capital (9.5% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.48B | CN¥4.20B | CN¥1.19B | CN¥1.01B | CN¥823M |
| Revenue growth | — | +253% | +18% | +23% | — |
| Gross profit | CN¥4.19B | CN¥3.82B | CN¥836M | CN¥743M | CN¥564M |
| EBITDA | n/a | CN¥3.24B | CN¥335M | CN¥287M | CN¥85.0M |
| Net income | CN¥3.09B | CN¥2.90B | CN¥705M | CN¥295M | CN¥49.3M |
| Free cash flow | CN¥181M | CN¥2.94B | CN¥484M | CN¥203M | CN¥42.3M |
| Capital expenditure | CN¥276M | CN¥253M | CN¥281M | CN¥236M | CN¥221M |
| Total debt | CN¥0 | CN¥0 | CN¥50.0M | CN¥50.0M | CN¥150M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | $4.47B | -34% | +227% | 74% | 46.9× | 3.3% |
| 3SBio 1530.HK | $4.92B | -34% | +102% | 61% | 13.7× | n/a |
| Innovent Biologics 1801.HK | $19.2B | -5% | +43% | 17% | 53.3× | 11.7% |
| Bio-Thera Solutions 688177.SS | $1.10B | -14% | +24% | -44% | n/a | n/a |
| Shanghai Henlius Biotech 2696.HK | $3.41B | -37% | +33% | 12% | 23.8× | 15.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688336.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.2% | +6.5% | 3rd lowest of 20 |
| 6-month return | -34.1% | +3.7% | 2nd lowest of 20 |
| Distance from 52-week high | -50.1% | -28.5% | 3rd lowest of 21 |
| Revenue growth (TTM) | +227.2% | +9.1% | 2nd highest of 19 |
| Operating margin | 73.8% | 17.6% | highest of 19 |
| Forward P/E | 46.9× | 26.9× | 3rd most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 3.3% | 10.4% | 7th least demanding of 16 |
| Growth delivered (Del g) | +45.1% | +7.5% | 4th highest of 16 |
| Hurdle (Req g minus delivered) | -41.8 pp | -3.2 pp | 3rd least demanding of 16 |
| ROIC minus cost of capital | +23.7 pp | +7.3 pp | 4th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $4.47B | -34% | +227% | 74% | 46.9× | 3.3% | +45.1% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.47B | +33% | +21% | 16% | 33.9× | 14.9% | +12.7% |
| Definium Therapeutics DFTX | United States | $4.47B | +51% | n/a | n/a | n/a | n/a | n/a |
| Camurus CAMX.ST | Sweden | $4.52B | +47% | 0% | 37% | 48.5× | 10.4% | +46.5% |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.53B | +2% | +12% | 33% | 35.9× | 25.2% | +5.5% |
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $4.53B | -17% | +60% | -4% | 64.5× | n/a | n/a |
| Guangzhou Baiyunshan Pharmaceutical 0874.HK | Hong Kong | $4.56B | -23% | +6% | 3% | 7.3× | 0.7% | +4.0% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.37B | +7% | +25% | 25% | 32.2× | 23.8% | +13.8% |
| HanmiPharm 128940.KS | South Korea | $4.36B | +2% | +14% | 16% | 16.8× | 5.0% | +7.5% |
| Humanwell Healthcare (Group) 600079.SS | China | $4.71B | +3% | -3% | 16% | 13.4× | -6.8% | +3.0% |
| Travere Therapeutics TVTX | United States | $4.76B | +16% | +49% | -3% | 16.9× | 16.7% | +19.9% |
| Novast Laboratories 301569.SZ | China | $4.82B | n/a | +3% | 27% | n/a | 42.6% | +3.1% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $4.11B | +4% | -13% | 20% | 31.4× | 17.8% | -5.8% |
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $4.08B | -39% | +36% | -14% | n/a | n/a | n/a |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.05B | +6% | -4% | 32% | 14.9× | -11.5% | +0.3% |
| Yuhan 000100.KS | South Korea | $4.05B | -12% | +5% | 5% | 38.6× | 20.2% | +6.2% |
| Siegfried SFZN.SW | Switzerland | $3.98B | -10% | +4% | 16% | 17.8× | n/a | n/a |
| Liquidia LQDA | United States | $3.97B | +5% | +2,234% | 37% | 32.9× | 0.7% | +192.5% |
| Erasca ERAS | United States | $5.04B | +42% | n/a | n/a | n/a | n/a | n/a |
| SKBP 326030.KS | South Korea | $5.12B | -11% | +39% | 35% | 21.6× | 0.5% | +93.6% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.89B | +15% | +3% | 20% | 22.3× | 1.5% | +12.1% |